Go, no-go decision making for phase 3 clinical trials: ACT IV revisited

Affiliations

¹ School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.
² School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA. Electronic address: hirobins@wisc.edu.

Comment

Huy Tram N Nguyen et al. Lancet Oncol. 2017 Dec.

. 2017 Dec;18(12):e708.

doi: 10.1016/S1470-2045(17)30857-4.

¹ School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.
² School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA. Electronic address: hirobins@wisc.edu.

No abstract available

Comment in

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH. Weller M, et al. Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2. Lancet Oncol. 2017. PMID: 29208433 No abstract available.

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Weller M, et al. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28844499 Clinical Trial.